

TESARO Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 19-Jun-2013

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 10

 Phase 3 Clinical..... 11

 Phase 2 Clinical..... 19

 Phase 1 Clinical..... 26

 Discovery..... 34

 Suspended..... 38

[Return to Table of Contents](#)

TESARO Inc

COMPANY OVERVIEW

Company Name	TESARO Inc
Parent Company Name	TESARO Inc
Website	http://tesarobio.com/
Country	US
Number of Drugs in Active Development	5
Number of Inactive Drugs	0
Number of Patents as Owner	2
Number of Patents as Third Party	0
Number of Deals	3
Key Indications	Cancer,Advanced solid tumor,Breast tumor,Chemotherapy induced nausea and vomiting,Chemotherapy-induced emesis,Chronic lymphocytic leukemia,Cough,Emesis,Glioblastoma,Mantle cell lymphoma,Metastatic prostate cancer,Nausea,Ovary tumor,Prolymphocytic leukemia,Stage IV
Key Target-based Actions	Anaplastic lymphoma kinase receptor inhibitor
Key Technologies	Fluorescence,Hybridization technology

COMPANY PROFILE

SUMMARY

TESARO is a biopharmaceutical company focused on developing treatments for cancer.

FINANCIAL

In February 2013, TESARO began an underwritten public offering of \$75 million of its common stock. At that time, the company expected to grant the underwriters an option to buy an additional \$11.25 million common stock shares to cover the over allotments; later that month, the company priced the offering of an aggregate of 4,720,000 common stock shares at \$18 per share, to raise gross proceeds of approximately \$85 million. TESARO also granted a 30-day overallotment option to the underwriters to buy an additional 708,000 common stock shares. Net proceeds of approximately \$79.2 million was expected from the offering and was expected to close on or about March 05, 2013. In March 2013, the company raised net proceeds of \$91.2 million from the closed public offering.

In June 2012, TESARO was to begin trading on NASDAQ under the tickertape symbol TSRO on June 28, 2012, with an initial public offering of 6 million shares of its common stock at a per share price of \$13.50. The offer was to close on July 03, 2012. Underwriters were to be granted 30-day option to purchase up to an additional 0.9 million shares of common stock to cover overallotments.

In June 2011, the company secured \$101 million in a series B financing.

In May 2010, the company secured \$60 million in start-up funding. At that time, the company raised \$20 million in series A financing.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	3	0	3
Gastrointestinal disease	2	0	2
Gynecology and obstetrics	1	0	1
Andrology	1	0	1
Dermatological disease	1	0	1
Genitourinary disease	1	0	1
Respiratory disease	1	0	1
Toxicity and intoxication	1	0	1
Hematological disease	1	0	1
Endocrine disease	1	0	1
Immune disorder	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Phase 2 Clinical	1
Phase 1 Clinical	1
Discovery	1
Suspended	1

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	0	0	3	0	3
Drug - Development Services	0	0	3	0	3

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Gastrointestinal disease	4	4
Neoplasm	1	2
Genitourinary disease	1	1
Gynecology and obstetrics	1	1
Endocrine disease	1	1
Respiratory disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 3	4	4
Phase 1	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

[Return to Table of Contents](#)



Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Gastrointestinal disease	1	0	1
Immune disorder	1	0	1
Psychiatric disorder	1	0	1
Neoplasm	1	0	1
Neurological disease	2	0	2
Respiratory disease	1	0	1
Inflammatory disease	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

rolapitant (oral), TESARO

rolapitant (oral), TESARO SNAPSHOT

Drug Name	rolapitant (oral), TESARO
Key Synonyms	rolapitant;rolapitant hydrochloride
Originator Company	Schering-Plough Corp
Active Companies	TESARO Inc
Inactive Companies	Schering-Plough Corp;OPKO Health Inc
Highest Status	Phase 3 Clinical
Active Indications	Chemotherapy-induced emesis;Emesis;Cough;Nausea
Target-based Actions	NK1 receptor antagonist
Other Actions	Anti-emetic;Anxiolytic;Antidepressant;Antitussive
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	15-Feb-2013

rolapitant (oral), TESARO DEVELOPMENT PROFILE

SUMMARY

TESARO, under license from OPKO Health (which was under license from Schering-Plough), is developing rolapitant (SCH-619734; structure shown), the lead in a series of oral NK1 receptor antagonists, for the potential prevention of chemotherapy-induced or post-operative nausea and vomiting (CINV/PONV), and the treatment of cough. In March 2012, a phase III CINV trial began. In October 2012, a second phase III trial began. In October 2012, a third phase III trial began ; in February 2013, results from the three pivotal trials were expected in the second half of 2013. In September 2006, a phase II trial for emesis was initiated. In January 2007, a phase II trial for chronic cough commenced.

By October 2009, a phase I trial of another compound from this series was underway however, no further development of this compound has been reported.

Schering-Plough had also previously investigated other cyclic urea derivative NK1 antagonists, including SCH-388714 and SCH-425078, initially for the potential treatment of anxiety and depression. However, no development has been reported for these compounds or indications since 2005.

The company is also investigating iv formulation of rolapitan for the prevention of CINV.

[Return to Table of Contents](#)



rolapitant (oral), TESARO DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
TESARO Inc	Chemotherapy-induced emesis	US	Phase 3 Clinical	16-Mar-2012
TESARO Inc	Cough	UK	Phase 2 Clinical	14-Dec-2010
TESARO Inc	Emesis	US	Phase 2 Clinical	14-Dec-2010
TESARO Inc	Nausea	US	Phase 2 Clinical	14-Dec-2010
OPKO Health Inc	Chemotherapy-induced emesis	Australia	Discontinued	14-Dec-2010
OPKO Health Inc	Chemotherapy-induced emesis	Canada	Discontinued	14-Dec-2010
OPKO Health Inc	Chemotherapy-induced emesis	Europe	Discontinued	14-Dec-2010
OPKO Health Inc	Chemotherapy-induced emesis	Far East	Discontinued	14-Dec-2010
OPKO Health Inc	Chemotherapy-induced emesis	South Africa	Discontinued	14-Dec-2010
OPKO Health Inc	Chemotherapy-induced emesis	South America	Discontinued	14-Dec-2010
OPKO Health Inc	Cough	UK	Discontinued	14-Dec-2010
OPKO Health Inc	Emesis	US	Discontinued	14-Dec-2010
Schering-Plough Corp	Chemotherapy-induced emesis	Australia	Discontinued	04-Nov-2009
Schering-Plough Corp	Chemotherapy-induced emesis	Canada	Discontinued	04-Nov-2009
Schering-Plough Corp	Chemotherapy-induced emesis	Europe	Discontinued	04-Nov-2009
Schering-Plough Corp	Chemotherapy-induced emesis	Far East	Discontinued	04-Nov-2009
Schering-Plough Corp	Chemotherapy-induced emesis	South Africa	Discontinued	04-Nov-2009
Schering-Plough Corp	Chemotherapy-induced emesis	South America	Discontinued	04-Nov-2009
Schering-Plough Corp	Cough	UK	Discontinued	04-Nov-2009
Schering-Plough Corp	Emesis	US	Discontinued	04-Nov-2009
Schering-Plough Corp	Anxiety disorder	US	No Development Reported	06-Sep-2007
Schering-Plough Corp	Depression	US	No Development Reported	06-Sep-2007


rolapitant (oral), TESARO CHEMICAL STRUCTURES

[Return to Table of Contents](#)




CAS Registry Number:	Confidence Level:
552292-08-7	2
	
Name	Type
rolapitant	INN

CAS Registry Number:	Confidence Level:
914462-92-3	2
	
Name	Type
rolapitant hydrochloride	USAN
SCH-619734	Research Code

CAS Registry Number:	Confidence Level:
	3
	
Name	Type
SCH-388714	Research Code

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
	4
	
Name	Type
SCH-714758	Research Code

rolapitant (oral), TESARO DRUG NAMES

Names	Type
rolapitant	INN
rolapitant hydrochloride	USAN
SCH-714758	Research Code
SCH-388714	Research Code
SCH-425078	Research Code
rolapitant (oral, emesis), Schering-Plough	
NK1 receptor antagonists, Schering-Plough	
SCH-619734	Research Code
rolapitant (oral), TESARO	
rolapitant (iv, emesis), Schering-Plough	

rolapitant (oral), TESARO CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Chemotherapy-induced emesis											
0	0	3	3	0	0	0	0	0	0	3	3

[Return to Table of Contents](#)

Emesis											
0	0	0	0	0	2	0	0	0	0	0	2
Nausea											
0	0	0	0	0	2	0	0	0	0	0	2
Cough											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	3	3	0	3	0	0	0	0	3	6

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
OPKO Health Inc	1	0	0	1	2
TESARO Inc	0	0	1	0	1
Merck & Co Inc	0	1	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Asset Divestment	0	1	1
Drug - Development/Commercialization License	1	0	1

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Merck & Co Inc	8	1	8
OPKO Health Inc	6	0	6
TESARO Inc	1	0	1
Individual	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	4
Product (derivative)	2
Process	2
Product	1

TSR-011

TSR-011 SNAPSHOT

Drug Name	TSR-011
Key Synonyms	
Originator Company	Amgen Inc
Active Companies	TESARO Inc
Inactive Companies	Amgen Inc
Highest Status	Phase 2 Clinical
Active Indications	Cancer
Target-based Actions	Anaplastic lymphoma kinase receptor inhibitor
Other Actions	Anticancer protein kinase inhibitor
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	26-Apr-2013

TSR-011 DEVELOPMENT PROFILE

SUMMARY

TESARO, under license from Amgen, is developing TSR-011, the lead from a series of oral, small molecule, anaplastic lymphoma kinase (ALK) inhibitors, including and TSR-012, for the potential treatment of ALK positive cancers including NSCLC. In November 2012, first patient was dosed in a phase I/II trial .


TSR-011 DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
TESARO Inc	Cancer	US	Phase 2 Clinical	01-Nov-2012
Amgen Inc	Cancer	US	Discontinued	22-Mar-2011

TSR-011 CHEMICAL STRUCTURES

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
	3
	

CAS Registry Number:	Confidence Level:
	3
	

TSR-011 DRUG NAMES

Names	Type
TSR-012	Research Code
TSR-011	Research Code
ALK inhibitors (oral, non-small cell lung cancer), Amgen/TESARO	
anaplastic lymphoma kinase inhibitors (oral, non-small cell lung cancer), TESARO	

TSR-011 CLINICAL TRIALS

Trials by Phase and Condition Studied

[Return to Table of Contents](#)

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Metastatic non small cell lung cancer											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	1	0	0	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

TSR-011 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Amgen Inc	1	0	0	0	1
TESARO Inc	0	0	1	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
TESARO Inc	1	0	1

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Tentative	1

niraparib

niraparib SNAPSHOT

Drug Name	niraparib
Key Synonyms	niraparib
Originator Company	Merck & Co Inc
Active Companies	Merck & Co Inc;TESARO Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Mantle cell lymphoma;Advanced solid tumor;Polymorphocytic leukemia;Chronic lymphocytic leukemia;Ovary tumor;Stage IV melanoma;Breast tumor;Glioblastoma;Metastatic prostate cancer
Target-based Actions	Poly ADP ribose polymerase 2 inhibitor;Poly ADP ribose polymerase 1 inhibitor
Other Actions	DNA repair inhibitor;Anticancer
Technologies	Oral formulation;Capsule formulation;Small molecule therapeutic
Last Change Date	22-May-2013

niraparib DEVELOPMENT PROFILE

SUMMARY

Merck & Co and TESARO are developing niraparib (formerly MK-4827; structure shown), a poly ADP-ribose polymerase (PARP)-1/-2 inhibitor, for the potential oral treatment of cancer, including ovarian cancer, glioblastoma and melanoma. In September 2008, a phase I trial in advanced solid tumors, including ovarian cancer, began; this trial was later expanded to include patients with other solid tumors and hematological malignancies; in November 2012, final results were presented. In February 2013, the company planned to initiate a phase III trial in platinum-sensitive ovarian cancer patients in mid-2013. In April 2013, the company expected to initiate a phase III trial in breast cancer patients with germline BRCA mutations in 2H13. By February 2011, a planned phase II mantle-cell lymphoma trial had been withdrawn prior to enrollment and between July 2011 and November 2011, three further phase I trials were terminated early. However, in February 2011, another phase I trial was initiated in patients with advanced glioblastoma multiforme and advanced melanoma; in December 2011, the trial was ongoing.

niraparib DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Merck & Co Inc	Advanced solid tumor	Japan	Phase 1 Clinical	30-Nov-2010
Merck & Co Inc	Advanced solid tumor	US	Phase 1 Clinical	09-Dec-2008
Merck & Co Inc	Chronic lymphocytic leukemia	US	Phase 1 Clinical	24-Mar-2011

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Merck & Co Inc	Glioblastoma	US	Phase 1 Clinical	28-Feb-2011
Merck & Co Inc	Metastatic prostate cancer	US	Phase 1 Clinical	02-Dec-2009
Merck & Co Inc	Ovary tumor	US	Phase 1 Clinical	09-Dec-2008
Merck & Co Inc	Prolymphocytic leukemia	US	Phase 1 Clinical	24-Mar-2011
Merck & Co Inc	Stage IV melanoma	US	Phase 1 Clinical	28-Feb-2011
TESARO Inc	Advanced solid tumor	US	Phase 1 Clinical	04-Sep-2012
TESARO Inc	Chronic lymphocytic leukemia	US	Phase 1 Clinical	04-Sep-2012
TESARO Inc	Glioblastoma	US	Phase 1 Clinical	04-Sep-2012
TESARO Inc	Metastatic prostate cancer	US	Phase 1 Clinical	04-Sep-2012
TESARO Inc	Ovary tumor	US	Phase 1 Clinical	04-Sep-2012
TESARO Inc	Prolymphocytic leukemia	US	Phase 1 Clinical	04-Sep-2012
TESARO Inc	Stage IV melanoma	US	Phase 1 Clinical	04-Sep-2012
Merck & Co Inc	Breast tumor	US	Discovery	25-Apr-2013
Merck & Co Inc	Mantle cell lymphoma	US	Discovery	17-Nov-2010
TESARO Inc	Breast tumor	US	Discovery	25-Apr-2013
TESARO Inc	Mantle cell lymphoma	US	Discovery	04-Sep-2012


niraparib CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
	2
	
Name	Type
niraparib	INN; USAN
MK-4827	Research Code


[Return to Table of Contents](#)

Name	Type
1038915-60-4	

CAS Registry Number:	Confidence Level:
	3



CAS Registry Number:	Confidence Level:
	3



niraparib DRUG NAMES

Names	Type
PARP-1/-2 inhibitor (oral, cancer), Merck & Co/TESARO	
niraparib	INN, USAN
1038915-60-4	
MK-4827	Research Code

[Return to Table of Contents](#)

niraparib CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Advanced solid tumor											
0	0	0	0	0	0	0	3	0	1	0	4
Ovary tumor											
0	0	1	1	0	0	0	2	0	0	1	3
Solid tumor											
0	0	0	0	0	0	0	2	0	0	0	2
Peritoneal tumor											
0	0	1	1	0	0	0	0	0	0	1	1
Fallopian tube cancer											
0	0	1	1	0	0	0	0	0	0	1	1
Mantle cell lymphoma											
0	0	0	0	0	1	0	0	0	0	0	1
Hematological neoplasm											
0	0	0	0	0	0	0	1	0	0	0	1
Melanoma											
0	0	0	0	0	0	0	1	0	0	0	1
Glioblastoma											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	1	1	0	1	0	6	0	1	1	9

[Return to Table of Contents](#)

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

niraparib DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
TESARO Inc	0	0	4	0	4
European Organisation for Research and Treatment of Cancer (EORTC)	1	0	0	0	1
Breast International Group	1	0	0	0	1
European Network of Gynaecological Oncological Trial Groups	1	0	0	0	1
Merck & Co Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development Services	3	0	3
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Individual	2	0	2
Merck & Co Inc	2	0	2
Illumina Inc	1	0	1
Amgen Inc	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	1
General interest	1
Product (derivative)	1

[Return to Table of Contents](#)

rolapitant (iv, CINV), TESARO

rolapitant (iv, CINV), TESARO SNAPSHOT

Drug Name	rolapitant (iv, CINV), TESARO
Key Synonyms	rolapitant
Originator Company	Schering-Plough Corp
Active Companies	TESARO Inc
Inactive Companies	Schering-Plough Corp;OPKO Health Inc
Highest Status	Discovery
Active Indications	Chemotherapy induced nausea and vomiting
Target-based Actions	NK1 receptor antagonist
Other Actions	Anti-emetic
Technologies	Intravenous formulation;Small molecule therapeutic
Last Change Date	15-Feb-2013

rolapitant (iv, CINV), TESARO DEVELOPMENT PROFILE

SUMMARY

TESARO is investigating iv formulation of rolapitant which was originally licensed from OPKO Health (which was under license from Schering-Plough), the lead in a series of oral NK1 receptor antagonists, for the potential prevention of chemotherapy-induced nausea and vomiting (CINV),,. In February 2013, the company planned to initiate clinical development of the drug later that year .

The company is also developing an oral formulation of rolapitant for the prevention of chemotherapy-induced or post-operative nausea and vomiting and treatment of cough.

rolapitant (iv, CINV), TESARO DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
TESARO Inc	Chemotherapy induced nausea and vomiting	US	Discovery	07-Sep-2012
OPKO Health Inc	Chemotherapy induced nausea and vomiting	US	Discontinued	14-Oct-2010
Schering-Plough Corp	Chemotherapy induced nausea and vomiting	US	Discontinued	13-Oct-2009

rolapitant (iv, CINV), TESARO CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
552292-08-7	2
	
Name	Type
rolapitant	INN


rolapitant (iv, CINV), TESARO DRUG NAMES

Names	Type
rolapitant	INN
rolapitant (iv, CINV), Schering-Plough	
rolapitant (iv, CINV), TESARO	
rolapitant (iv, CINV), OPKO Health	

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
OPKO Health Inc	1	0	0	1	2
Merck & Co Inc	0	1	0	0	1
TESARO Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1
Drug - Asset Divestment	0	1	1

MK-2512

MK-2512 SNAPSHOT

Drug Name	MK-2512
Key Synonyms	
Originator Company	Merck & Co Inc
Active Companies	TESARO Inc
Inactive Companies	Merck & Co Inc
Highest Status	Suspended
Active Indications	Cancer
Target-based Actions	Poly ADP ribose polymerase 2 inhibitor;Poly ADP ribose polymerase 1 inhibitor
Other Actions	Anticancer;DNA repair inhibitor
Technologies	Small molecule therapeutic
Last Change Date	04-Mar-2013

MK-2512 DEVELOPMENT PROFILE

SUMMARY

TESARO, under license from Merck, was investigating MK-2512, a poly ADP-ribose polymerase (PARP)-1/-2 inhibitor and back-up compound for niraparib, for the potential treatment of cancer. However, in June 2012, the company was not advancing the drug at that time.

MK-2512 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
TESARO Inc	Cancer	US	Suspended	27-Jun-2012
Merck & Co Inc	Cancer	US	Discontinued	31-May-2012

MK-2512 DRUG NAMES


Names	Type
MK-2512	Research Code
PARP 1/2 inhibitor (cancer), TESARO	

[Return to Table of Contents](#)

MK-2512 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
TESARO Inc	0	0	1	0	1
Merck & Co Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

